RLAY - Relay Therapeutics, Inc. Stock Price and Quote

RLAY [NASD]

Index	-	P/E	-	EPS (ttm)	-2.69	Insider Own	1.20%	Shs Outstand	120.89M	Perf Week	6.32%
Market Cap	2.60B	Forward P/E	-	EPS next Y	-3.05	Insider Trans	-20.17%	Shs Float	115.44M	Perf Month	51.84%
Income	-290.50M	PEG	-	EPS next Q	-0.70	Inst Own	-	Short Float / Ratio	16.16% / 14.22	Perf Quarter	-0.55%
Sales	1.70M	P/S	1527.22	EPS this Y	-49.40%	Inst Trans	1.58%	Short Interest	18.66M	Perf Half Y	7.25%
Book/sh	9.01	P/B	2.43	EPS next Y	-11.30%	ROA	-28.90%	Target Price	36.20	Perf Year	2.48%
Cash/sh	8.88	P/C	2.46	EPS next 5Y	-	ROE	-33.00%	52W Range	12.65 - 35.36	Perf YTD	46.45%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-40.60%	52W High	-38.12%	Beta	-
Dividend %	-	Quick Ratio	15.20	Sales past 5Y	-	Gross Margin	-	52W Low	72.96%	ATR	1.21
Employees	320	Current Ratio	15.20	Sales Q/Q	-57.10%	Oper. Margin	-	RSI (14)	71.27	Volatility	6.10% 6.81%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-15.60%	Profit Margin	-	Rel Volume	1.10	Prev Close	20.19
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 03 AMC	Payout	-	Avg Volume	1.31M	Price	21.88
Recom	2.10	SMA20	21.84%	SMA50	23.74%	SMA200	7.76%	Volume	1,437,757	Change	8.37%

Sep-30-22

Initiated

Barclays

Equal Weight

$23

Sep-02-22

Initiated

Stifel

Buy

$40

Jun-06-22

Initiated

Jefferies

Underperform

$13

Feb-01-22

Initiated

Berenberg

Buy

$45

Jul-21-21

Initiated

BofA Securities

Buy

$50

Dec-15-20

Reiterated

H.C. Wainwright

Buy

$54 → $57

Dec-08-20

Initiated

JMP Securities

Mkt Outperform

$66

Nov-05-20

Initiated

H.C. Wainwright

Buy

$54

Aug-10-20

Initiated

JP Morgan

Neutral

$36

Aug-10-20

Initiated

Guggenheim

Buy

$48

Show Previous Ratings

Jan-13-23 11:11AM	Relay Therapeutics, Inc. (RLAY) Soars 20.7%: Is Further Upside Left in the Stock? Zacks
Jan-03-23 07:30AM	Relay Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-31-22 08:53AM	Relay Therapeutics, Inc.'s (NASDAQ:RLAY) Intrinsic Value Is Potentially 23% Below Its Share Price Simply Wall St.
Nov-24-22 08:02AM	Will Relay Therapeutics (NASDAQ:RLAY) Spend Its Cash Wisely? Simply Wall St.
Nov-17-22 01:58PM	Alphabet Inc (GOOGL) Investment Portfolio: Top 15 Companies Insider Monkey
07:30AM	Loading…
Nov-07-22 07:30AM	Relay Therapeutics to Participate in Two Upcoming Investor Conferences GlobeNewswire
Nov-03-22 06:35PM	Relay Therapeutics, Inc. (RLAY) Reports Q3 Loss, Lags Revenue Estimates Zacks
04:05PM	Relay Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights GlobeNewswire
Oct-27-22 04:05PM	Relay Therapeutics to Announce Third Quarter 2022 Financial Results and Corporate Highlights GlobeNewswire
Oct-14-22 10:14AM	Relay Therapeutics (NASDAQ:RLAY shareholders incur further losses as stock declines 11% this week, taking one-year losses to 44% Simply Wall St.
Sep-26-22 07:30AM	Relay Therapeutics to Participate in Fireside Chat at Bank of America Securities 2022 Precision Oncology Conference GlobeNewswire
Sep-23-22 07:30AM	7 Unknown Biotech Stocks That Could Rocket in 2023 InvestorPlace
Sep-12-22 09:30PM	Relay Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire
07:00AM	Relay Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
06:30AM	Foundation Medicine and Relay Therapeutics Collaborate to Develop FoundationOne®CDx as a Companion Diagnostic for Relays Investigational FGFR2 Inhibitor, RLY-4008 Business Wire
09:45AM	Loading…
Sep-11-22 09:45AM	Late Breaking Data Presented at ESMO Congress 2022 Demonstrate Potential of RLY-4008 to Transform Treatment Options for Cholangiocarcinoma Patients with FGFR2-Driven Disease GlobeNewswire
Sep-08-22 04:06PM	Relay Therapeutics Jumps on Data Update TheStreet.com +23.75%
10:25AM	Relay Therapeutics Shares Jump After Interim Data From Bile Duct Cancer Drug Ahead Of ESMO Presentation Benzinga
Aug-30-22 11:15AM	For This AI Drug Developer, Look Beyond the Rally TheStreet.com -5.43%
Aug-25-22 02:48PM	Relay Therapeutics Stock Shows Market Leadership With Jump To 94 RS Rating Investor's Business Daily
Aug-18-22 04:05PM	Relay Therapeutics to Present Clinical Data on RLY-4008 at ESMO Congress GlobeNewswire
Aug-04-22 04:05PM	Relay Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights GlobeNewswire
Jul-28-22 04:05PM	Relay Therapeutics to Announce Second Quarter 2022 Financial Results and Corporate Highlights GlobeNewswire -5.73%
Jun-27-22 06:00AM	Relay Therapeutics Discloses Anticipated Registrational Path for RLY-4008 in Cholangiocarcinoma and Growing Breast Cancer Franchise at Virtual Analyst and Investor Event GlobeNewswire -10.54%
Jun-16-22 07:30AM	Relay Therapeutics Announces Timing of Virtual Analyst and Investor Event GlobeNewswire
May-26-22 07:30AM	Relay Therapeutics to Participate in Two Upcoming Investor Conferences GlobeNewswire
May-07-22 09:59AM	Relay Therapeutics (NASDAQ:RLAY shareholders incur further losses as stock declines 13% this week, taking one-year losses to 30% Simply Wall St.
May-05-22 04:05PM	Relay Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights GlobeNewswire -9.06%
May-03-22 07:30AM	Relay Therapeutics to Participate in Fireside Chat at Bank of America Securities 2022 Healthcare Conference GlobeNewswire
Apr-28-22 04:05PM	Relay Therapeutics to Announce First Quarter 2022 Financial Results and Corporate Highlights GlobeNewswire
04:05PM	Loading…
Feb-24-22 04:05PM	Relay Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights GlobeNewswire +5.91%
Feb-17-22 04:05PM	Relay Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights GlobeNewswire
Feb-10-22 11:51AM	Bargain Shopping? 3 Strong Buy Stocks That Are Down Over 50% TipRanks -5.91%
Feb-02-22 07:30AM	Relay Therapeutics to Participate in Two Upcoming Investor Conferences GlobeNewswire -5.07%
Jan-04-22 07:30AM	Relay Therapeutics Announces Dosing of First Patient in First-in-Human Trial of RLY-2608 and Initiation of Expansion Cohorts for First-In-Human Trial of RLY-4008 GlobeNewswire
Jan-03-22 07:30AM	Relay Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference GlobeNewswire +5.37%
Dec-22-21 11:11AM	Biotech: Interest in vaccine stocks will probably wane, strategist says Yahoo Finance Video
Dec-18-21 12:38AM	Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ... GuruFocus.com
Dec-10-21 07:30AM	Relay Therapeutics Announces Preclinical Data that Support Clinical Development of RLY-2608 as Both a Single Agent and in Combination GlobeNewswire
Nov-17-21 11:39AM	Notable Relay Therapeutics Insider Trades $890K In Company Stock Benzinga
Nov-16-21 12:36PM	How Many Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Do Institutions Own? Simply Wall St.
Nov-10-21 04:05PM	Relay Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights GlobeNewswire
Nov-04-21 04:05PM	Relay Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Highlights GlobeNewswire
08:14AM	Section 32 Raises $740 Million Venture Fund PR Newswire
Oct-27-21 01:23PM	J.P. Morgan Sees These 3 Strong Buy Stocks Climbing Over 50% TipRanks
04:50AM	10 Pharma Stocks to Buy According to Mark Lamperts Biotechnology Value Fund Insider Monkey
Oct-15-21 09:01AM	Why Relay Therapeutics Is Up 30% This Week Motley Fool -6.85%
Oct-12-21 09:58PM	Relay Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire -5.22%
04:27AM	5 Stocks To Watch For October 12, 2021 Benzinga
Oct-11-21 04:15PM	Relay Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
Oct-08-21 12:24PM	Relay Therapeutics Highlights Interim Data From Bile Duct Cancer Trial Benzinga +8.31%
06:00AM	Relay Therapeutics Announces Interim Clinical Data that Support RLY-4008 as a Highly Selective FGFR2 Inhibitor GlobeNewswire
Oct-07-21 08:50AM	Relay Therapeutics Announces Preclinical Data that Support RLY-2608 as the First Known Allosteric Pan-Mutant Selective Inhibitor of PI3K GlobeNewswire -11.86%
Sep-13-21 06:00AM	Relay Therapeutics to Present Clinical Data on RLY-4008 and Preclinical Data on RLY-2608 at AACR-NCI-EORTC Molecular Targets Conference GlobeNewswire +11.04%
Aug-18-21 10:27AM	Time To Worry? Analysts Are Downgrading Their Relay Therapeutics, Inc. (NASDAQ:RLAY) Outlook Simply Wall St.
Aug-15-21 04:06AM	Relay Therapeutics, Inc. (NASDAQ:RLAY) Consensus Forecasts Have Become A Little Darker Since Its Latest Report Simply Wall St.
Aug-12-21 04:05PM	Relay Therapeutics Announces Corporate Updates and Reports Second Quarter 2021 Financial Results GlobeNewswire
Aug-05-21 04:05PM	Relay Therapeutics to Announce Second Quarter 2021 Financial Results and Recent Corporate Highlights GlobeNewswire
Jul-20-21 10:48PM	Is Relay Therapeutics, Inc. (RLAY) A Good Stock To Buy? Insider Monkey
Jul-19-21 09:26AM	Relay Therapeutics (NASDAQ:RLAY) Share Prices Have Dropped 24% In The Last Year Simply Wall St.
Jun-02-21 06:00AM	Relay Therapeutics to Participate in Two Upcoming Investor Conferences GlobeNewswire
May-14-21 06:00AM	Relay Therapeutics to Participate in Fireside Chat at the Cowen 2nd Annual Oncology Innovation Summit GlobeNewswire +6.15%
May-13-21 04:05PM	Relay Therapeutics Reports First Quarter 2021 Financial Results GlobeNewswire
May-10-21 06:00AM	Relay Therapeutics Strengthens Computational Leadership Team with Addition of Patrick Riley, Ph.D. GlobeNewswire -6.07%
May-05-21 06:00AM	Relay Therapeutics to Participate in Fireside Chat at Bank of America 2021 Health Care Conference GlobeNewswire
May-03-21 06:00AM	Relay Therapeutics Expands Clinical Leadership Team with Addition of Tara OMeara and Charles Ferté GlobeNewswire
Apr-16-21 11:31AM	Relay Therapeutics Inks $85M Deal To Buy ZebiAI SmarterAnalyst
06:00AM	Relay Therapeutics Extends Leadership in Integrating Computational and Experimental Approaches to Create Precision Medicines by Acquiring ZebiAI GlobeNewswire
Apr-14-21 05:57AM	Are Insiders Buying Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock? Simply Wall St. +6.51%
Mar-25-21 04:05PM	Relay Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights GlobeNewswire
Mar-10-21 04:30PM	Relay Therapeutics to Present Preclinical Data on RLY-4008 at AACR Annual Meeting GlobeNewswire +6.18%
Feb-04-21 04:05PM	Relay Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2021 Oncology Day GlobeNewswire
Jan-14-21 04:26AM	We Think Relay Therapeutics (NASDAQ:RLAY) Can Easily Afford To Drive Business Growth Simply Wall St.
Jan-06-21 05:00PM	SoftBanks Son Is Poised for Another IPO Windfall in 2021 Bloomberg
06:00AM	Relay Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-16-20 10:36PM	Is RLAY A Good Stock To Buy Now? Insider Monkey
Dec-14-20 06:00AM	Relay Therapeutics Announces a Worldwide License and Collaboration Agreement with Genentech for RLY-1971 GlobeNewswire -12.47%
Nov-12-20 04:05PM	Relay Therapeutics Reports Third Quarter 2020 Financial Results GlobeNewswire
Oct-16-20 10:53AM	Are Insiders Buying Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock? Simply Wall St. +8.13%
Sep-03-20 04:05PM	Relay Therapeutics Announces Dosing of First Patient in First-in-Human Clinical Trial of RLY-4008, a Highly Selective FGFR2 Inhibitor GlobeNewswire
Aug-27-20 06:50AM	Relay Therapeutics Reports Second Quarter 2020 Financial Results GlobeNewswire
Aug-16-20 08:59AM	Goldman Sachs: These 3 Stocks Can Deliver Big Returns for Investors TipRanks
Aug-11-20 06:40AM	SoftBank Moves Into Asset Management After Return to Profits Bloomberg
Aug-06-20 06:07PM	Sons SoftBank Poised to Return to Profit After Big Losses Bloomberg +8.40%
Jul-20-20 04:05PM	Relay Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Jul-17-20 04:17PM	Berkeley Lights IPO Jumps By Triple Digits As Hot Biotech Begins Trading Investor's Business Daily +25.48%
Jul-16-20 04:28PM	Relay Therapeutics IPO Raises $400 Million As Stock Soars Investor's Business Daily
01:25PM	Word on the street: These two IPOs might be worth investing in Yahoo Finance Video
12:02PM	Relay Therapeutics's stock sprints out of the gate, after upsized IPO priced above recently raised expectations MarketWatch
Jul-15-20 08:51PM	Relay Therapeutics Announces Pricing of Initial Public Offering GlobeNewswire
07:34AM	Relay Therapeutics upsizes and raises proposed price range for IPO MarketWatch

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Patel Sanjiv	President and CEO	Jan 19	Option Exercise	5.04	28,000	141,120	282,554	Jan 19 08:33 PM
Patel Sanjiv	President and CEO	Jan 19	Sale	20.02	28,000	560,560	254,554	Jan 19 08:33 PM
Patel Sanjiv	President and CEO	Jan 18	Option Exercise	5.04	28,000	141,120	282,554	Jan 19 08:33 PM
Patel Sanjiv	President and CEO	Jan 18	Sale	20.87	28,000	584,360	254,554	Jan 19 08:33 PM
Patel Sanjiv	President and CEO	Jan 17	Option Exercise	5.04	28,000	141,120	282,554	Jan 19 08:33 PM
Patel Sanjiv	President and CEO	Jan 17	Sale	20.23	28,000	566,440	254,554	Jan 19 08:33 PM
Adams Brian	Chief Legal Officer	Jan 12	Sale	20.00	9,994	199,880	51,531	Jan 13 04:05 PM
Catinazzo Thomas	Chief Financial Officer	Dec 27	Sale	14.49	445	6,448	50,231	Dec 28 04:13 PM
Bergstrom Donald A	President, R&D	Dec 27	Sale	14.49	980	14,200	85,886	Dec 28 04:09 PM
Adams Brian	Chief Legal Officer	Dec 27	Sale	14.49	295	4,275	61,525	Dec 28 04:07 PM
Patel Sanjiv	President and CEO	Nov 10	Option Exercise	4.44	28,000	124,399	272,729	Nov 10 05:13 PM
Patel Sanjiv	President and CEO	Nov 10	Sale	20.00	28,000	560,000	254,554	Nov 10 05:13 PM
Patel Sanjiv	President and CEO	Nov 08	Option Exercise	4.12	14,000	57,680	268,554	Nov 10 05:13 PM
Patel Sanjiv	President and CEO	Nov 08	Sale	20.18	14,000	282,520	254,554	Nov 10 05:13 PM
Bergstrom Donald A	President, R&D	Nov 01	Option Exercise	4.12	8,000	32,960	94,866	Nov 01 05:58 PM
Bergstrom Donald A	President, R&D	Nov 01	Sale	22.75	8,000	182,000	86,866	Nov 01 05:58 PM
Bergstrom Donald A	President, R&D	Oct 28	Sale	21.54	1,817	39,138	86,866	Nov 01 05:58 PM
Adams Brian	Chief Legal Officer	Oct 28	Sale	21.54	728	15,681	61,820	Nov 01 05:56 PM
Porter Andy	Chief Administrative Officer	Oct 28	Sale	21.54	448	9,650	45,164	Nov 01 06:03 PM
Catinazzo Thomas	Chief Financial Officer	Oct 28	Sale	21.54	1,099	23,672	50,676	Nov 01 06:01 PM
Patel Sanjiv	President and CEO	Oct 13	Option Exercise	4.12	14,000	57,680	268,554	Oct 13 06:09 PM
Patel Sanjiv	President and CEO	Oct 13	Sale	20.58	14,000	288,120	254,554	Oct 13 06:09 PM
Patel Sanjiv	President and CEO	Oct 12	Option Exercise	4.12	14,000	57,680	268,554	Oct 13 06:09 PM
Patel Sanjiv	President and CEO	Oct 12	Sale	21.18	14,000	296,520	254,554	Oct 13 06:09 PM
Patel Sanjiv	President and CEO	Oct 11	Option Exercise	4.12	14,000	57,680	268,554	Oct 13 06:09 PM
Patel Sanjiv	President and CEO	Oct 11	Sale	21.36	14,000	299,040	254,554	Oct 13 06:09 PM
Bergstrom Donald A	President, R&D	Oct 03	Option Exercise	4.12	8,000	32,960	96,683	Oct 04 04:22 PM
Bergstrom Donald A	President, R&D	Oct 03	Sale	22.43	8,000	179,440	88,683	Oct 04 04:22 PM
Porter Andy	Chief Administrative Officer	Sep 27	Sale	22.73	259	5,887	45,612	Sep 29 05:14 PM
Catinazzo Thomas	Chief Financial Officer	Sep 27	Sale	22.73	443	10,069	51,775	Sep 29 05:10 PM
Bergstrom Donald A	President, R&D	Sep 27	Sale	22.73	976	22,184	88,683	Sep 29 05:07 PM
Adams Brian	Chief Legal Officer	Sep 27	Sale	22.73	294	6,683	62,548	Sep 29 05:04 PM
Patel Sanjiv	President and CEO	Sep 15	Option Exercise	4.12	14,000	57,680	268,554	Sep 15 09:02 PM
Patel Sanjiv	President and CEO	Sep 15	Sale	23.80	14,000	333,200	254,554	Sep 15 09:02 PM
Patel Sanjiv	President and CEO	Sep 14	Option Exercise	4.12	14,000	57,680	268,554	Sep 15 09:02 PM
Patel Sanjiv	President and CEO	Sep 14	Sale	23.47	14,000	328,580	254,554	Sep 15 09:02 PM
Patel Sanjiv	President and CEO	Sep 13	Option Exercise	4.12	14,000	57,680	268,554	Sep 15 09:02 PM
Patel Sanjiv	President and CEO	Sep 13	Sale	25.45	14,000	356,300	254,554	Sep 15 09:02 PM
Bergstrom Donald A	President, R&D	Sep 08	Option Exercise	4.12	25,000	103,000	114,659	Sep 08 08:22 PM
Catinazzo Thomas	Chief Financial Officer	Sep 08	Option Exercise	4.12	26,257	108,179	78,475	Sep 08 08:26 PM
Murcko Mark	Director	Sep 08	Sale	29.95	25,000	748,750	996,952	Sep 08 08:31 PM
Catinazzo Thomas	Chief Financial Officer	Sep 08	Sale	30.00	26,257	787,710	52,218	Sep 08 08:26 PM
Bergstrom Donald A	President, R&D	Sep 08	Sale	30.00	25,000	750,000	89,659	Sep 08 08:22 PM
Bergstrom Donald A	President, R&D	Sep 02	Option Exercise	4.12	4,900	20,188	94,559	Sep 02 05:47 PM
Bergstrom Donald A	President, R&D	Sep 02	Sale	25.46	4,900	124,754	89,659	Sep 02 05:47 PM
Bergstrom Donald A	President, R&D	Sep 01	Option Exercise	4.12	8,100	33,372	97,759	Sep 01 08:26 PM
Bergstrom Donald A	President, R&D	Sep 01	Sale	23.07	8,100	186,867	89,659	Sep 01 08:26 PM
Bergstrom Donald A	President, R&D	Aug 24	Option Exercise	4.12	15,000	61,800	104,659	Aug 25 05:23 PM
Bergstrom Donald A	President, R&D	Aug 24	Sale	25.00	15,000	375,000	89,659	Aug 25 05:23 PM
Bergstrom Donald A	President, R&D	Aug 05	Option Exercise	4.12	8,000	32,960	97,659	Aug 08 05:38 PM
Bergstrom Donald A	President, R&D	Aug 05	Sale	20.00	8,000	160,000	89,659	Aug 08 05:38 PM
Porter Andy	Chief Administrative Officer	Jul 28	Sale	21.27	452	9,614	45,871	Jul 29 04:57 PM
Catinazzo Thomas	Chief Financial Officer	Jul 28	Sale	21.26	734	15,605	52,218	Jul 29 04:53 PM
Bergstrom Donald A	President, R&D	Jul 28	Sale	21.27	1,835	39,030	89,659	Jul 29 04:45 PM
Adams Brian	Chief Legal Officer	Jul 28	Sale	21.27	734	15,612	62,842	Jul 29 04:42 PM
Bergstrom Donald A	President, R&D	Jul 06	Option Exercise	4.12	8,000	32,960	99,494	Jul 08 04:17 PM
Bergstrom Donald A	President, R&D	Jul 06	Sale	20.00	8,000	160,000	91,494	Jul 08 04:17 PM
Porter Andy	Chief Administrative Officer	Jun 27	Sale	20.31	265	5,382	46,323	Jun 28 06:03 PM
Catinazzo Thomas	Chief Financial Officer	Jun 27	Sale	20.31	300	6,093	52,952	Jun 28 05:59 PM
Adams Brian	Chief Legal Officer	Jun 27	Sale	20.31	300	6,093	63,576	Jun 28 05:56 PM
Bergstrom Donald A	President, R&D	Jun 27	Sale	20.31	999	20,290	91,494	Jun 28 05:53 PM
Bergstrom Donald A	President, R&D	Jun 24	Option Exercise	4.12	8,000	32,960	100,493	Jun 28 05:53 PM
Bergstrom Donald A	President, R&D	Jun 24	Sale	20.00	8,000	160,000	92,493	Jun 28 05:53 PM
Bergstrom Donald A	President, R&D	May 02	Option Exercise	4.12	13,000	53,560	105,493	May 02 08:24 PM
Bergstrom Donald A	President, R&D	May 02	Sale	24.62	13,000	320,060	92,493	May 02 08:24 PM
Bergstrom Donald A	President, R&D	Apr 28	Sale	25.57	1,811	46,307	92,493	May 02 08:24 PM
Porter Andy	Chief Administrative Officer	Apr 28	Sale	25.57	435	11,123	46,588	May 02 08:13 PM
Catinazzo Thomas	Chief Financial Officer	Apr 28	Sale	25.57	725	18,538	53,252	May 02 08:07 PM
Adams Brian	Chief Legal Officer	Apr 28	Sale	25.57	708	18,104	63,876	May 02 08:03 PM
Patel Sanjiv	President and CEO	Apr 14	Option Exercise	4.58	28,000	128,240	267,740	Apr 14 09:20 PM
Patel Sanjiv	President and CEO	Apr 14	Sale	30.51	28,000	854,280	253,740	Apr 14 09:20 PM
Patel Sanjiv	President and CEO	Apr 13	Option Exercise	4.58	28,000	128,240	267,740	Apr 14 09:20 PM
Patel Sanjiv	President and CEO	Apr 13	Sale	31.95	28,000	894,600	253,740	Apr 14 09:20 PM
Patel Sanjiv	President and CEO	Apr 12	Option Exercise	4.12	28,000	115,360	281,740	Apr 14 09:20 PM
Patel Sanjiv	President and CEO	Apr 12	Sale	31.80	28,000	890,400	253,740	Apr 14 09:20 PM
Bergstrom Donald A	President, R&D	Apr 01	Option Exercise	4.12	18,000	74,160	112,304	Apr 05 05:32 PM
Bergstrom Donald A	President, R&D	Apr 01	Sale	30.32	18,000	545,760	94,304	Apr 05 05:32 PM
Porter Andy	Chief Administrative Officer	Mar 29	Sale	29.87	294	8,782	47,023	Mar 31 05:49 PM
Catinazzo Thomas	Chief Financial Officer	Mar 29	Sale	29.87	282	8,423	53,977	Mar 31 05:45 PM
Adams Brian	Chief Legal Officer	Mar 29	Sale	29.87	333	9,947	64,584	Mar 31 05:37 PM
Bergstrom Donald A	President, R&D	Mar 29	Sale	29.87	622	18,579	94,304	Mar 31 05:41 PM
Catinazzo Thomas	Chief Financial Officer	Mar 24	Option Exercise	4.12	13,286	54,738	67,545	Mar 28 08:18 PM
Bergstrom Donald A	President, R&D	Mar 24	Option Exercise	4.12	10,000	41,200	104,926	Mar 28 08:11 PM
Catinazzo Thomas	Chief Financial Officer	Mar 24	Sale	30.00	13,286	398,580	54,259	Mar 28 08:18 PM
Bergstrom Donald A	President, R&D	Mar 24	Sale	30.00	10,000	300,000	94,926	Mar 28 08:11 PM
Bergstrom Donald A	President, R&D	Mar 10	Option Exercise	4.12	10,000	41,200	104,926	Mar 11 07:02 PM
Bergstrom Donald A	President, R&D	Mar 10	Sale	25.00	10,000	250,000	94,926	Mar 11 07:02 PM
Bergstrom Donald A	President, R&D	Mar 01	Option Exercise	4.12	8,000	32,960	102,926	Mar 03 05:31 PM
Bergstrom Donald A	President, R&D	Mar 01	Sale	23.88	8,000	191,040	94,926	Mar 03 05:31 PM
Bergstrom Donald A	President, R&D	Feb 22	Option Exercise	4.12	8,000	32,960	117,920	Feb 22 09:01 PM
Bergstrom Donald A	President, R&D	Feb 22	Sale	20.94	22,994	481,577	94,926	Feb 22 09:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience